NCT02331433View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

APN1125

APN1125 orally at ascending doses

DRUG

Placebo

Matching Placebo

Trial Locations (1)

91206

PAREXEL Early Phase, Glendale

Sponsors

Lead Sponsor

CoMentis

Collaborators (1)

Alpharmagen, Inc.
All Listed Sponsors
collaborator

Alpharmagen, Inc.

INDUSTRY

lead

CoMentis

INDUSTRY